Rain Therapeutics to Present at IASLC 2021 World Conference on Lung Cancer and Participate in Panel Discussion at Citi 16th Annual Biopharma Virtual Conference
September 01 2021 - 8:00AM
Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage
company developing precision oncology therapeutics, today announced
it will be presenting a poster at the virtual IASLC 2021 World
Conference on Lung Cancer (#WCLC21) being held September 8-14,
2021. Avanish Vellanki, co-founder, chairman and chief executive
officer of Rain, will also participate in a Targeted Oncology Panel
Discussion at the Citi 16th Annual Biopharma Conference being held
September 8-10, 2021.
Additional details can be found below:
IASLC 2021 World Conference on Lung
CancerPoster Title: The MDM2/p53 axis is
a therapeutic vulnerability in malignant pleural
mesotheliomaPresenter: Lynn Heasley, Ph.D.,
University of Colorado Anschutz Medical CampusUnited States of
America Date: Wednesday, September 8, 2021
Citi 16th Annual
Biopharma Virtual Conference Targeted Oncology Panel
DiscussionDate: Friday, September 10,
2021Time: 6:45 – 7:30 a.m.
PTLocation: Company’s website (click here)
A copy of the poster and a replay of the panel discussion will
be available by visiting the "Events & Presentations" section
of the Rain website after the conclusion of the presentations and
will be archived on the Rain website for 30 days.
About Rain Therapeutics Inc.Rain Therapeutics
Inc. is a late-stage precision oncology company developing
therapies that target oncogenic drivers for which it is able to
genetically select patients it believes will most likely benefit.
This approach includes using a tumor-agnostic strategy to select
patients based on their tumors’ underlying genetics rather than
histology. Rain’s lead product candidate, milademetan (RAIN-32), is
a small molecule, oral inhibitor of MDM2, which is oncogenic in
numerous cancers. In addition to milademetan, Rain is also
developing a preclinical program that is focused on inducing
synthetic lethality in cancer cells by inhibiting RAD52.
Media ContactJordyn TemperatoLifeSci
Communications+1.646.876.5196jtemperato@lifescicomms.com
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Apr 2023 to Apr 2024